Introduction
Crohn's disease and ulcerative colitis are chronic inflammatory bowel diseases (IBD) caused by inflammation of the gastrointestinal tract with an increasing prevalence in the Western world. The aetiology is unknown but environmental factors (including diet and the gut microbiota), a genetic predisposition and immune dysfunction all have a crucial role in the relapsing and remitting nature of IBD. Symptoms include abdominal pain, diarrhoea, fatigue, malabsorption and weight loss, all of which are debilitating and have a huge negative effect on quality of life. Treatment of IBD involves a multidisciplinary approach comprising medical management and sometimes surgery. Diet is central to IBD management (1, 2) ; however, there are many uncertainties for optimal dietary provision for different types and stages of IBD. A UK collaborative partnership within the James Lind Alliance was set up between patients, clinicians and other stakeholders to develop research priorities in IBD (3) . The James Lind Alliance priority setting partnership provides a framework based on a transparent, democratic and reproducible process for developing research priorities and this project was the first to be carried out in gastroenterology. The purpose of the overall project was to identify unanswered questions about IBD treatment from the patient and clinical perspectives and to prioritise those that patients and clinicians agreed were the most important. The aim of this short report is to provide a summary of the research priority findings relating to diet in the treatment of IBD to demonstrate what details are important to the IBD community.
Materials and methods
A detailed methodology for the development of research priorities following the James Lind Alliance process has been described elsewhere (3, 4) . Ethical approval was not required. In brief, a steering committee was set up in November 2013 comprising two patients with IBD; two gastroenterologists; two IBD specialist nurses; two colorectal surgeons; two dietitians; a representative from the UK inflammatory bowel disease charity organisation, Crohn's and Colitis UK; a representative of the James Lind Alliance; and an administrator.
A questionnaire survey was developed by the steering committee and invited participants to provide up to five treatment uncertainties (defined as 'known unknowns') anonymously. It was piloted amongst IBD patients and IBD specialist nurses for ease of use. The survey was available in electronic or paper format and was advertised widely in IBD patient and healthcare professional networks between March and May 2014. Target participants were IBD patients, carers, IBD specialist nurses, gastroenterologists, surgeons and dietitians. Completion of the survey implied consent to take part. Any uncertainties not represented from the survey results but registered on the UK Database of Uncertainties about the Effects of Treatments; Research Recommendations from Cochrane Systematic Reviews; and the National Institute for Health and Care Excellence were added.
The initial list of uncertainties was revised noting original participant group representation (i.e. patient/carer or healthcare professional). Similar treatment uncertainties were combined to create 'indicative uncertainties'. Nonquestions (e.g. statements or comments); uncertainties unrelated to IBD or IBD treatment (e.g. aetiology that was outside scope); indicative uncertainties mentioned by only one respondent; and uncertainties that could already be resolved by published systematic reviews were removed. Remaining uncertainties were reviewed and refined into a standard format by members of the steering committee using the Health Research Classification Scheme and, where there were differences in opinion regarding the meaning of the uncertainty, agreement was sought by consensus.
After the list of 70 indicative uncertainties determined by the process above, steering group members and the wider partnership participated in a survey to vote for their top five research questions and rank them in order of priority for research. The wider partnership comprised British Society of Gastroenterology members, patients, carers and members of other societies: Royal College of Nursing, Core Charity, Crohn's and Colitis UK, Royal College of General Practitioners, Association of Coloproctology of Great Britain and Ireland, British Dietetic Association. A priority list of 25 questions was established by the steering group based on frequency of votes and rank order.
The top 10 research questions for IBD were developed during a final workshop of steering group members and partner organisations to ensure a balance of patients and clinicians. Members of the National Institute for Health Research (NIHR) were also included for discussion purposes but only patients and clinicians had voting rights. Participants were divided into four groups made up of a mixture of patients, clinicians and researchers. Each group discussed several treatment uncertainties and ranked then in order of priority and were led by an independent facilitator to ensure that all participants had an opportunity to express their opinion. The whole group ranked the overall set of uncertainties through active debate until consensus was reached regarding the uncertainties to be removed and the order of the final 10 research priorities. Finally, several focused research questions, based on 'PICO' (Participants, Intervention, Comparator, Outcome) were developed.
Results
A total of 1671 uncertainties from 531 participants and known uncertainties were collected in the initial survey.
Following validation and refinement, 418 uncertainties were removed. Of the remaining 1253, 348 were categorised as diet-related and grouped according to topic (Table 1) . Seventy-two percent of diet-related questions came from patients, followed by 16% from healthcare professionals in secondary care, then 6% from carers and 3% from healthcare professionals in primary care, and the remaining 3% of responders did not indicate. There were 206 uncertainties related to how diet can be used to treat IBD or alleviate symptoms.
When the diet-related uncertainties were collated and revised, seven diet-related indicative uncertainties were created (Table 2 ). These indicative uncertainties were ranked as part of 70 indicative uncertainties which formed the second survey and are reported elsewhere (3) . All seven dietrelated indicative uncertainties from Table 2 were within the 25 highest ranked questions. These top 25 questions were subsequently voted on at the final meeting for inclusion in the final top 10 research priorities. Two diet-specific (positions 3 and 7) and one broadly diet-related (position 10) treatment uncertainties for IBD were included in the final top 10 research priorities (Table 3) .
Discussion
The findings of the present study confirm that dietary treatment options in the management of IBD are important research priorities for both clinicians and patients. The role of diet in IBD was strongly supported by patients, with almost three-quarters of diet-related questions coming from patients. The majority of topics related directly to how diet can impact disease activity and symptom control. This agrees with three previous research studies that have assessed the importance of diet from the patients' perspective (5) (6) (7) . These studies showed that 51-82% of patients reported problems in relation to food and nutrition. Two other recent research priority setting initiatives did not prioritise diet in the top 10, possibly as a result of a lack of patient representation. (8, 9) The first study included 14 patients from the USA and 258 gastroenterologists from around the world. (8) They asked for up to three important comparative effectiveness research topics. Seven of the top 10 were directly related to pharmaceutical treatments; the investigators report that comparing the effectiveness of competing dietary interventions was only in the top 15 proposed by patients who comprised only 5% of all respondents. The second study invited non-medical professionals, predominantly nurses from European Crohn's and Colitis Organisation (ECCO), to suggest research questions from five themes. (9) Their study's final top 10 did not include any diet-related questions and the investigators indicated the under-prioritising of diet was likely to be related to the low number of dietitians participating in the survey; however, diet topics did reach their final 44 questions.
The relationship between diet, the gut microbiota and interactions with the immune system are of paramount importance (10) and this research demonstrates that these are important to the IBD community by the wide range of diet-related topics. Furthermore, the current evidence (1, 11) and guidelines (2, 12, 13) for the dietary management of IBD do not cover these treatment uncertainties; therefore, publication of this comprehensive list of diet-related topics is justified. Furthermore, addressing these research priorities will provide support for developing more IBD specific dietetic posts that are urgently needed to meet the needs of patients. (1, 6, 7, 14) The robust methodology demonstrated by The James Lind Alliance Priority Setting Partnership shows that engaging with a diverse mix of stakeholders from various roles, ages and ethnic groups, including patients and all members involved in multidisciplinary teams in IBD, is philosophically correct and gives the resultant priorities legitimacy. Thus, it is imperative to report the complete set of diet and nutrition research priorities to ensure that research funding bodies are aware of this research need for future commissioned calls. Taken from main research findings paper (1) . IBD, inflammatory bowel disease. Taken from main research findings paper (1) . IBD, inflammatory bowel disease.
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